Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
暂无分享,去创建一个
A G Sorensen | A. Sorensen | E. Gasparetto | R. Domingues | L. C. Hygino da Cruz | I. Rodriguez | R C Domingues | L C Hygino da Cruz | I Rodriguez | E L Gasparetto | R. C. Domingues | I. Rodríguez | L. Cruz
[1] P. Wen,et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. , 2009, Cancer research.
[2] Timothy D Johnson,et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[4] T. Cloughesy,et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy , 2006, Neurology.
[5] A. Sahgal,et al. Pseudoprogression Following Chemoradiotherapy for Glioblastoma Multiforme , 2010, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[6] A. Alavi,et al. PET imaging for differentiating recurrent brain tumor from radiation necrosis. , 2005, Radiologic clinics of North America.
[7] Bart Neyns,et al. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. , 2009, Surgical neurology.
[8] Dieta Brandsma,et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.
[9] P. Wen,et al. Response criteria for glioma , 2008, Nature Clinical Practice Oncology.
[10] Dieta Brandsma,et al. Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide , 2008, Cancer.
[11] R. Gonzalez,et al. Clinical and radiographic features of peritumoral infarction following resection of glioblastoma , 2006, Neurology.
[12] S. Karimi,et al. Pseudoprogression (PsPr) after concurrent radiotherapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma multiforme (GBM) , 2008 .
[13] B. Drayer,et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? , 1998, AJNR. American journal of neuroradiology.
[14] M. J. van den Bent,et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression , 2004, Neurology.
[15] P Van Tassel,et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. , 2000, Radiology.
[16] M. J. van den Bent,et al. Pseudoprogression and pseudoresponse in the treatment of gliomas , 2009, Current opinion in neurology.
[17] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] P. Sundgren. MR Spectroscopy in Radiation Injury , 2009, American Journal of Neuroradiology.
[19] Tracy T Batchelor,et al. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. , 2010, Neuro-oncology.
[20] R. Jain,et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer , 2009, Nature Reviews Clinical Oncology.
[21] A. Brandes,et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. , 2008, Neuro-oncology.
[22] P. Box. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma , 2010 .
[23] Matthew S. Brown,et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.
[24] N. Burnet,et al. Interpretation of Early Imaging after Concurrent Radiotherapy and Temozolomide for Glioblastoma , 2007 .
[25] William D Rooney,et al. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. , 2011, International journal of radiation oncology, biology, physics.
[26] P. Wen,et al. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression , 2009, Journal of Neuro-Oncology.
[27] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[29] Dushyant V. Sahani,et al. Biomarkers of response and resistance to antiangiogenic therapy , 2009, Nature Reviews Clinical Oncology.
[30] M. Mrugala,et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. , 2009, Neurology.
[31] Thomas L Chenevert,et al. Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. , 2006, Magnetic resonance imaging.
[32] M. Chamberlain. Pseudoprogression in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Susan Chang,et al. Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging , 2009, Current neurology and neuroscience reports.
[34] A. Brandes,et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Brandes,et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.